Provided by Tiger Trade Technology Pte. Ltd.

Cytokinetics

69.95
-2.1400-2.97%
Volume:804.41K
Turnover:56.66M
Market Cap:9.72B
PE:-9.74
High:71.79
Open:71.54
Low:69.76
Close:72.09
52wk High:88.31
52wk Low:44.91
Shares:139.02M
Float Shares:138.02M
Volume Ratio:1.04
T/O Rate:0.58%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.1827
EPS(LYR):-6.5400
ROE:-572.15%
ROA:-28.09%
PB:-56.05
PE(LYR):-10.70

Loading ...

Cytokinetics Q1 EPS $(1.67) Misses $(1.64) Estimate, Sales $19.355M Beat $8.518M Estimate.

Benzinga Earnings
·
May 06

Cytokinetics CFO Sung Lee sells 23,906 shares for $1.84 million

Reuters
·
May 06

Cytokinetics Inc - Announces Proposed $650 Mln Common Stock Offering

THOMSON REUTERS
·
May 06

Cytokinetics EVP, Chief Commercial Officer Andrew Callos disposes 11,333 shares for $875,372.25

Reuters
·
May 06

BRIEF-Cytokinetics Q1 Basic EPS USD -1.67

Reuters
·
May 06

Cytokinetics Reports First Quarter 2026 Financial Results and Provides Business Update

GlobeNewswire
·
May 06

Cytokinetics Is Maintained at Buy by Needham

Dow Jones
·
May 06

Cytokinetics Shares Surge Over 20% on Positive Heart Drug Trial Results

Stock News
·
May 05

Cytokinetics price target raised to $106 from $92 at Truist

TIPRANKS
·
May 05

Cytokinetics report ‘arguably a best-case scenario’ for Edgewise, says Stifel

TIPRANKS
·
May 05

Cytokinetics Phase 3 data bodes well for Edgewise, says Raymond James

TIPRANKS
·
May 05

Cytokinetics Shares Jump 15.8% After Heart Disease Drug Meets Main Goals in Late-Stage Study

THOMSON REUTERS
·
May 05

This Is Why Cytokinetics Stock (CYTK) Soared Today

TIPRANKS
·
May 05

Cytokinetics Rises After Promising Late-Stage Trial of Heart Drug

Dow Jones
·
May 05

BUZZ-Cytokinetics jumps as heart disease drug meets goals in late-stage trial

Reuters
·
May 05

Cytokinetics Shares up 23.7% Premarket After Heart Disease Drug Meets Main Goals in Late-Stage Study

THOMSON REUTERS
·
May 05

Cytokinetics says Phase 3 ACACIA-HCM trial of aficamten meets dual primary endpoints

Reuters
·
May 05

Cytokinetics Inc - No New Safety Signals Identified; Completion Rates Similar for Aficamten and Placebo

THOMSON REUTERS
·
May 05

Cytokinetics Inc - Acacia-HCM Meets Dual Primary Endpoints in Kccq-Css and Maximal Exercise Performance at Week 36

THOMSON REUTERS
·
May 05

Cytokinetics Announces Positive Topline Results From Acacia-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Non-Obstructive Hypertrophic Cardiomyopathy

THOMSON REUTERS
·
May 05